# TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

Source: https://onco.cc/trials/nct06125522/  
OnCo record `nct06125522` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Vepdegestrant in advanced solid tumours, run by Pfizer, active and no longer recruiting.

## Summary

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) is a phase 1/2 interventional study registered as NCT06125522 by Pfizer, with 11 participants enrolled, started 2024-01-10 and due to reach its primary completion in 2026-12-31. Interventions recorded: vepdegestrant and Samuraciclib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06125522
- Phase: 1/2
- Setting: TACTIVE-U: AN INTERVENTIONAL SAFETY AND EFFICACY PHASE 1B/2, OPEN-LABEL UMBRELLA STUDY TO INVESTIGATE TOLERABILITY, PK, AND ANTITUMOR ACTIVITY OF VEPDEGESTRANT (ARV-471/PF-07850327), AN ORAL PROTEOLYSIS TARGETING CHIMERA, IN COMBINATION WITH OTHER ANTICANCER TREATMENTS IN PARTICIPANTS AGED 18 AND OLDER WITH ER+ ADVANCED OR METASTATIC BREAST CANCER, SUB-STUDY C (ARV-471 IN COMBINATION WITH SAMURACICLIB)
- Sponsor: Pfizer
- Enrolled: 11

## Sources

- ClinicalTrials.gov NCT06125522: https://clinicaltrials.gov/study/NCT06125522

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Samuraciclib](https://onco.cc/drugs/samuraciclib/), [Vepdegestrant](https://onco.cc/drugs/vepdegestrant/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/nct06125522.json